NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $1.99 +0.08 (+4.19%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cellectis Stock (NASDAQ:CLLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cellectis alerts:Sign Up Key Stats Today's Range$1.87▼$1.9950-Day Range$1.75▼$2.4052-Week Range$1.70▼$3.77Volume210,835 shsAverage Volume50,263 shsMarket Capitalization$110.60 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Cellectis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks74th Percentile Overall ScoreCLLS MarketRank™: Cellectis scored higher than 74% of companies evaluated by MarketBeat, and ranked 417th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectis has only been the subject of 1 research reports in the past 90 days.Read more about Cellectis' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cellectis are expected to grow in the coming year, from ($0.54) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.28% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.28% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.01 News SentimentCellectis has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cellectis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address CLLS Stock News HeadlinesPromising Partnership and Pipeline Propel Cellectis SA to a Buy RatingNovember 8, 2024 | markets.businessinsider.comCellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comAI's Growing Energy Demands: The Urgent Need for Nuclear PowerAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. November 12, 2024 | The Bull Report (Ad)Cellectis SA: Strategic Advancements and Financial Strengths Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comCellectis price target lowered to $5 from $7 at BarclaysNovember 7, 2024 | markets.businessinsider.comCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingNovember 5, 2024 | globenewswire.comCellectis S.A. (CLLS) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comCellectis Provides Business Updates and Financial Results for Third Quarter 2024November 4, 2024 | globenewswire.comSee More Headlines CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS shares have decreased by 36.0% and is now trading at $1.97. View the best growth stocks for 2024 here. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) posted its earnings results on Monday, November, 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.03. The biotechnology company earned $18.05 million during the quarter, compared to analyst estimates of $5 million. Cellectis had a negative trailing twelve-month return on equity of 74.55% and a negative net margin of 234.39%. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Cellectis' major shareholders? Top institutional investors of Cellectis include Baillie Gifford & Co. (1.25%), Principal Financial Group Inc. (0.74%) and First Affirmative Financial Network (0.04%). How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA). Company Calendar Last Earnings11/04/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)5/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees290Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+255.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,060,000.00 Net Margins-234.39% Pretax Margin-235.80% Return on Equity-74.55% Return on Assets-22.65% Debt Debt-to-Equity Ratio0.48 Current Ratio1.78 Quick Ratio1.92 Sales & Book Value Annual Sales$9.19 million Price / Sales11.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.85Miscellaneous Outstanding Shares55,580,000Free Float46,463,000Market Cap$109.49 million OptionableOptionable Beta3.10 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:CLLS) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersAI's Growing Energy Demands: The Urgent Need for Nuclear PowerAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.